Home
Drugs
Bevacizumab
Clinical Trials

Clinical Trials Related to Bevacizumab

Related studies linked through entity extraction aliases.

A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma

Status: TERMINATED
Phase: PHASE3

A Study of Bevacizumab (Avastin) in Combination With Capecitabine (Xeloda) in Elderly Patients With Metastatic Colorectal Cancer

Status: COMPLETED
Phase: PHASE3

A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer

Status: COMPLETED
Phase: PHASE2

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Status: COMPLETED
Phase: PHASE3

Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

Status: COMPLETED
Phase: PHASE2

A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g)

Status: COMPLETED
Phase: PHASE2

Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer

Status: COMPLETED
Phase: PHASE2

A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain

Status: TERMINATED
Phase: PHASE2

A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER)

Status: COMPLETED
Phase: PHASE2

Enzastaurin, Carboplatin, and Gemcitabine With or Without Bevacizumab in Treating Patients With Recurrent, Stage IIIB, or Stage IV Non-Small Cell Lung Cancer

Status: WITHDRAWN
Phase: PHASE2

Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma

Status: WITHDRAWN
Phase: PHASE2

Randomized Phase III Study of Folfiri+Avastin Versus Xeliri+Avastin as 1st Line Treatment of CRC

Status: COMPLETED
Phase: PHASE3

Study of Biweekly Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model

Status: COMPLETED
Phase: PHASE1/PHASE2

Sirolimus and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Status: COMPLETED
Phase: PHASE1

Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

Status: COMPLETED
Phase: PHASE2

Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer

Status: COMPLETED
Phase: PHASE2

Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma

Status: COMPLETED
Phase: PHASE2

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

Status: COMPLETED
Phase: PHASE2

Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy

Status: COMPLETED
Phase: PHASE2

Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas

Status: COMPLETED
Phase: PHASE2